Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 56, Issue 6, Pages 3244-3249Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.06245-11
Keywords
-
Categories
Funding
- Australian Postgraduate award
- NHMRC [571917]
- Australian NHMRC
- Canada Institute of Health Research (CIHR)
Ask authors/readers for more resources
Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an ever-increasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine atninopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available